theory clinical_79_0
imports Main

begin

typedecl entity
typedecl event

consts
  Patient :: "entity ⇒ bool"
  TNBC :: "entity ⇒ bool"
  Immunotherapy :: "entity ⇒ bool"
  PARPInhibitors :: "entity ⇒ bool"
  Appropriate :: "entity ⇒ bool"
  For :: "entity ⇒ entity ⇒ bool"
  AsSecondLineTherapy :: "entity ⇒ bool"
  Combination :: "entity ⇒ bool"
  Vemurafenib :: "entity ⇒ bool"
  MEKInhibitor :: "entity ⇒ bool"
  Available :: "entity ⇒ bool"
  Carboplatin :: "entity ⇒ bool"
  Paclitaxel :: "entity ⇒ bool"
  Activity :: "entity ⇒ bool"
  Melanoma :: "entity ⇒ bool"
  Advanced :: "entity ⇒ bool"
  BRAFV600Mutation :: "entity ⇒ bool"
  BRAF :: "entity ⇒ bool"
  MEKInhibitors :: "entity ⇒ bool"
  Tolerated :: "event ⇒ bool"
  Agent :: "event ⇒ entity ⇒ bool"
  Demonstrates :: "event ⇒ bool"
  PredominantlyIn :: "entity ⇒ event ⇒ bool"
  IrrespectiveOfPriorTreatment :: "entity ⇒ entity ⇒ bool"
  Chemotherapy :: "entity ⇒ bool"
  Benefit :: "event ⇒ bool"
  Source :: "event ⇒ entity ⇒ bool"

(* Explanation 1: Patient with TNBC not appropriate for immunotherapy or PARP inhibitors as second line therapy. *)
axiomatization where
  explanation_1: "∃x y z. Patient x ∧ TNBC x ∧ Immunotherapy y ∧ PARPInhibitors z ∧ ¬Appropriate x ∧ For x y ∧ For x z ∧ AsSecondLineTherapy x"

(* Explanation 2: Combination vemurafenib and MEK inhibitor unavailable for patient. *)
axiomatization where
  explanation_2: "∃x y. Combination x ∧ Vemurafenib x ∧ MEKInhibitor x ∧ Patient y ∧ ¬Available x ∧ For x y"

(* Explanation 3: The combination of vemurafenib, carboplatin, and paclitaxel is well tolerated and demonstrates encouraging activity, predominantly in patients with advanced melanoma and BRAFV600 mutations irrespective of prior treatment with BRAF and/or MEK inhibitors. *)
axiomatization where
  explanation_3: "∃x y z w e1 e2. Combination x ∧ Vemurafenib x ∧ Carboplatin x ∧ Paclitaxel x ∧ Activity y ∧ Patient z ∧ Melanoma z ∧ Advanced z ∧ BRAFV600Mutation z ∧ BRAF w ∧ MEKInhibitors w ∧ Tolerated e1 ∧ Agent e1 x ∧ Demonstrates e2 ∧ Agent e2 x ∧ PredominantlyIn z e2 ∧ IrrespectiveOfPriorTreatment z w"

theorem hypothesis:
  assumes asm: "Patient x ∧ Combination y ∧ Vemurafenib y ∧ Chemotherapy y"
  (* Hypothesis: Patient may benefit from combination vemurafenib and chemotherapy. *)
  shows "∃x y e. Patient x ∧ Combination y ∧ Vemurafenib y ∧ Chemotherapy y ∧ Benefit e ∧ Agent e x ∧ Source e y"
proof -
  (* From the premise, we have known information about the patient, combination, vemurafenib, and chemotherapy. *)
  from asm have "Patient x ∧ Combination y ∧ Vemurafenib y ∧ Chemotherapy y" by blast
  (* Explanation 3 states that the combination of vemurafenib, carboplatin, and paclitaxel is well tolerated and demonstrates encouraging activity. *)
  (* This implies that the combination is beneficial, especially for patients with advanced melanoma and BRAFV600 mutations. *)
  (* Since the combination includes vemurafenib and chemotherapy, we can infer that it may benefit the patient. *)
  then have "Benefit e ∧ Agent e x ∧ Source e y" sledgehammer
  then show ?thesis <ATP>
qed

end
